Physician profile
Megan E Janson
NPI 1366738478
$1,484.27
in general payments reported to CMS, 2019-2025
29 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $461 · 2021: $98.00 · 2022: $128 · 2023: $87.26 · 2024: $120 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.37 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $163.45 | 2022-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $136.78 | 2020-2025 | |
| Amgen INC. | $113.69 | 2019-2025 | Evenity, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $76.59 | 2019-2020 | |
| Pfizer INC. | $74.60 | 2020-2025 | |
| Corium, LLC | $61.81 | 2025 | Azstarys |
| Gilead Sciences, INC. | $56.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $55.54 | 2020-2023 | Farxiga |
| Sanofi Pasteur INC. | $51.62 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $48.92 | 2020 | |
| Amarin Pharma, INC. | $47.37 | 2019 | |
| Allergan, INC. | $41.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.90 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sunovion Pharmaceuticals INC. | $32.63 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $28.97 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $28.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.91 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.59 | 2019 | |
| Astellas Pharma US INC | $22.56 | 2019 | |
| Ethicon US, LLC | $21.36 | 2020 | |
| Abbott Laboratories | $20.80 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $18.39 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $18.08 | 2020 | |
| Ucb, INC. | $16.51 | 2020 | |
| Eisai INC. | $16.42 | 2020 | |
| Endo Pharmaceuticals INC. | $16.39 | 2019 | |
| Glaxosmithkline, LLC. | $13.47 | 2025 | Bexsero, Shingrix, Arexvy |
| Zyla Life Sciences, INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Janson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.